Corona virus is quickly spreading around the world. The goal of viral management is to
disrupt the virus's life cycle, minimize lung damage, and alleviate severe symptoms …

Kinases are a group of therapeutic targets involved in the progression of numerous
diseases, including cancer, rheumatoid arthritis, Alzheimer's disease, and viral infections …

Abstract Coronavirus disease 2019 (COVID‐19) remains a major public health concern, and
vaccine unavailability, hesitancy, or failure underscore the need for discovery of efficacious …

The highly pathogenic, novel coronavirus disease (COVID-19) outbreak has emerged as a
once-in-a-century pandemic with poor consequences, urgently calling for new therapeutics …

The emergence of the COVID-19 pandemic has mandated the instant (re) search for
potential drug candidates. In response to the unprecedented situation, it was recognized …

We are witnessing a paradigm shift in drug development and clinical practice to fight the
novel coronavirus disease (COVID-19), and a number of clinical trials have been or are …

Baricitinib and imatinib are considered therapies for coronavirus disease 2019 (COVID‐19),
but their ultimate clinical impact remains to be elucidated, so our objective is to determine …

Background The efficacy and safety of baricitinib, an oral selective Janus kinase 1/2
inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID-19 is …

The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …

JAK inhibitors are novel treatment agents in the field of infectious diseases. One JAK
inhibitor, baricitinib has demonstrated significant clinical and survival benefits in hospitalized …